ArticleNeoplasia (New York, N.Y.)2021

Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo.

Franziska Briest et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.